sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Interests in Avadel Pharmaceuticals
The Vanguard Group, Inc. has made a disclosure under Form 8.3 regarding its interests in Avadel Pharmaceuticals plc. This disclosure is mandated by the Irish Takeover Panel under Rule 8.3 of the Irish Takeover Panel Act, 1997. It reveals Vanguard's involvement in relevant securities amounting to 5.67% of Avadel's US$0.01 ordinary shares, totaling 5,525,469 shares.
The form, dated October 22, 2025, confirms that The Vanguard Group holds no interests in other parties related to this offer, nor are there any cash-settled or stock-settled derivatives associated. Additionally, there are no indemnity, option arrangements, or agreements influencing these securities disclosed, supporting a straightforward position in Avadel's ordinary shares without any attached obligations or derivatives.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.